Calcium Signalling and PKC Activation: How EBC-46 Triggers Rapid Intracellular Calcium Flux
PKC activation by EBC-46 initiates a rapid calcium signalling cascade that contributes to tumour cell death, immune recruitment, and vascular disruption at the injection site.
When tigilanol tiglate (EBC-46) is injected into a solid tumour, one of the earliest measurable events is a sharp rise in intracellular calcium concentration. This calcium flux is not incidental — it is a direct consequence of protein kinase C (PKC) activation and a critical driver of the downstream events that destroy the tumour. [1]
PKC, Diacylglycerol, and the Calcium Connection
Protein kinase C is a family of serine/threonine kinases that regulate cell proliferation, apoptosis, and immune signalling. Classical PKC isoforms (α, βI, βII, γ) require both diacylglycerol (DAG) and calcium for full activation. EBC-46, as a DAG mimetic, binds the C1 domain of PKC with high affinity, locking the enzyme in its active conformation. This triggers phospholipase C (PLC) signalling, which cleaves PIP2 into IP3 and additional DAG — creating a positive feedback loop.
IP3 binds receptors on the endoplasmic reticulum, releasing stored calcium into the cytoplasm. The resulting calcium wave activates calcineurin, CaMKII, and other calcium-dependent enzymes that propagate the signal. [2]
Why Calcium Matters for Tumour Destruction
Sustained elevation of intracellular calcium is a well-characterised trigger of apoptosis. Mitochondria take up excess cytoplasmic calcium through the mitochondrial calcium uniporter (MCU), which depolarises the mitochondrial membrane, opens the permeability transition pore (mPTP), and releases cytochrome c into the cytoplasm. This initiates the intrinsic apoptotic cascade through caspase-9 and caspase-3 activation.
In the context of EBC-46, this mitochondrial calcium overload may explain the rapid onset of cell death observed in preclinical models — often within hours of injection, far faster than conventional chemotherapy agents that rely on DNA damage and cell-cycle arrest.
Calcium and Immune Cell Recruitment
Calcium signalling is also essential for immune cell activation. In neutrophils and macrophages, calcium flux drives degranulation, reactive oxygen species (ROS) production, and cytokine release. The inflammatory infiltrate observed at the EBC-46 injection site — characterised by a dense neutrophil response within 2–4 hours — is consistent with calcium-mediated immune activation.
T-cell activation likewise depends on calcium-NFAT signalling. While EBC-46's primary action is local, the immune microenvironment it creates may prime adaptive immunity against tumour antigens, a hypothesis currently under investigation in combination studies with checkpoint inhibitors. [3]
Vascular Disruption and Calcium-Dependent Contraction
Vascular smooth muscle contraction is calcium-dependent. PKC activation in endothelial and smooth muscle cells increases intracellular calcium, driving vasoconstriction and contributing to the vascular disruption that cuts off blood supply to the tumour. This haemorrhagic necrosis is visible within minutes of EBC-46 injection and is one of the most striking features of its mechanism of action.
The convergence of three calcium-dependent pathways — direct tumour cell apoptosis, immune recruitment, and vascular shutdown — creates a multi-pronged attack that is difficult for tumours to resist. Understanding the calcium signalling axis may also help researchers optimise dosing and predict which tumour types will respond best to tigilanol tiglate.
References
1. Boyle GM et al. (2014). Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumours in mouse models. PLoS ONE. doi.org
2. Cullen PJ & Bhatt SJ (2017). Protein kinase C signalling in cancer. Pharmacological Research. doi.org
3. Moses C et al. (2020). Immune response following intratumoural injection of EBC-46. Frontiers in Oncology. doi.org
